Dulanermin
As of the edition of 20 October 2026, Dulanermin is a protein: went quiet in 2018; acts on TNFRSF10A and TNFRSF10B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Protein
- Registered trials
- 5, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Dulanermin.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2006 to now |
| Roche | Lead sponsor of trials | 2006 to now |
| Gebaide Biotechnology | Lead sponsor of trials | 2016 to now |